(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.83%) $83.15
(-1.16%) $1.619
(-0.33%) $2 339.50
(-0.09%) $27.51
(0.53%) $927.00
(-0.19%) $0.933
(-0.23%) $11.00
(-0.26%) $0.798
(0.00%) $92.17
Live Chart Being Loaded With Signals
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors...
Stats | |
---|---|
今日成交量 | 1 450.00 |
平均成交量 | 6 785.00 |
市值 | 3.97M |
EPS | $-3.52 ( 2023-11-14 ) |
下一个收益日期 | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.240 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-18 | Catlin Michael | Buy | 18 000 | Restricted Stock Award |
2024-03-18 | Misajon Pamela | Buy | 18 000 | Restricted Stock Award |
2024-03-18 | Nagel Michael | Buy | 18 000 | Restricted Stock Award |
2023-10-05 | Bersani Pietro | Buy | 65 600 | Restricted Stock Units |
2023-10-05 | Misajon Pamela | Buy | 7 500 | Restricted Stock Units |
INSIDER POWER |
---|
100.00 |
Last 47 transactions |
Buy: 2 001 102 | Sell: 1 131 551 |
Kiromic BioPharma, Inc. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-19.09 |
FY | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-19.09 |
FY | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-70.12 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-5.68 |
Financial Reports:
No articles found.
Kiromic BioPharma, Inc.
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。